title: The risk-escalation model: a principled design strategy for early-phase trials.
abstract: Should first-in-human trials be designed to maximize the prospect of therapeutic benefit for volunteers, prioritize avoidance of unintended harms, or aim for some happy medium between the two? Perennial controversies surrounding initiation and design of early-phase trials hinge on how this question is resolved. In this paper, we build on the premise that the task of early-phase testing is to optimize various components of a potential therapy so that later, confirmatory trials have the maximal probability of informing drug development and clinical care. We then explore three strategies that investigators might use to manage trial risks while optimizing a therapy, using cell therapy for Amyotrophic Lateral Sclerosis (ALS) as an example. We argue that an iterative application of maximin strategies over successive cohorts and trials, which we call the "risk-escalation model," establishes a moral principle that should guide decision-making in early-phase trials.
authors.forename: Spencer Phillips
authors.initials: SP
authors.lastname: Hey
authors.forename: Jonathan
authors.initials: J
authors.lastname: Kimmelman
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy; D064987:Cell- and Tissue-Based Therapy / Q000009:adverse effects / Q000941:ethics; D002986:Clinical Trials as Topic / Q000941:ethics*; D017322:Clinical Trials, Phase II as Topic / Q000941:ethics; D017326:Clinical Trials, Phase III as Topic / Q000941:ethics; D003657:Decision Making / Q000941:ethics; D006801:Humans; D018579:Patient Selection / Q000941:ethics*; D012107:Research Design / Q000592:standards / Q000639:trends; D018570:Risk Assessment / Q000941:ethics* / Q000592:standards; D036302:Therapeutic Human Experimentation / Q000941:ethics*; D016896:Treatment Outcome; D035501:Uncertainty
references.citation: Science. 2009 Oct 16;326(5951):358-9
references.pmid: 19833936
references.citation: Amyotroph Lateral Scler. 2008;9(1):4-15
references.pmid: 18273714
references.citation: Mol Ther. 2007 Nov;15(11):1904-6
references.pmid: 17948045
references.citation: J Med Philos. 2007 Mar-Apr;32(2):79-98
references.pmid: 17454416
references.citation: J Clin Oncol. 2007 Jan 10;25(2):223-7
references.pmid: 17210944
references.citation: Nat Clin Pract Rheumatol. 2008 Jul;4(7):356-63
references.pmid: 18542108
references.citation: Science. 2009 May 8;324(5928):727-8
references.pmid: 19423804
references.citation: PLoS Med. 2010 Mar 30;7(3):e1000245
references.pmid: 20361020
references.citation: J Law Med Ethics. 2009 Spring;37(1):38-50
references.pmid: 19245601
references.citation: Regul Toxicol Pharmacol. 2010 Nov;58(2):243-51
references.pmid: 20558225
references.citation: Cell Stem Cell. 2011 May 6;8(5):476-8
references.pmid: 21549322
references.citation: Trials. 2012 Sep 22;13:173
references.pmid: 22999017
references.citation: Nat Rev Neurol. 2011 Dec 13;8(3):172-6
references.pmid: 22158518
references.citation: N Engl J Med. 2013 May 16;368(20):1949-50
references.pmid: 23593943
references.citation: Science. 2010 May 14;328(5980):829-30
references.pmid: 20466907
references.citation: J Transl Med. 2010 Jun 10;8:55
references.pmid: 20537174